NewDays published its latest clinical results.
Public source
Publisher name
Public post
Lisa Stiffler @ GeekWire on where NewDays is headed: the $16M seed close, our latest clinical results, and the randomized controlled trial we're running with Kaiser Perm…
Company
NewDays
AI-powered Cognitive Rehabilitation Therapy. Now available in WA, CA, FL, TX, NV, & NY!
- Industry
- Technology, Information and Internet
- Location
- Seattle, US
- Company size
- 11–50 employees
About NewDays
NewDays delivers personalized cognitive treatment that combines expert-led therapy with AI-powered daily practice for people experiencing mild cognitive impairment (MCI) or early dementia. Our science-backed, non-drug approach is designed to maintain cognitive function, build confidence, and help people live the way they want to live. Founded in 2024 by leaders from Amazon and Google X, NewDays makes clinically-validated cognitive interventions accessible through breakthrough AI technology and expert clinical oversight.
See moreLatest activity
Latest activity from NewDays
5 signals
Customers & Market
NewDays is now available in Nevada, its sixth state, offering cognitive treatment from home, covered by Medicare, telehealth visits with licensed clinicians, and daily AI-guided brain exercises for people living with mild cognitive impairment or dementia.
Research & Knowledge
NewDays is running a randomized controlled trial with Kaiser Permanente.
Presence & Recognition
NewDays is live in Nevada as of this week, marking its sixth state.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
MindMaze Therapeutics
MindMaze Therapeutics presented a two-year study with Vibra Healthcare at ASNR showing statistically significant improvements in mobility and self-care across multiple U.S. sites.
Research & Knowledge
Creyos
Creyos published an article examining the impact of earlier detection on dementia diagnosis, care planning, and treatment eligibility.
Research & Knowledge
Braingaze
Braingaze published a paper in GeroScience reporting on a 40Hz gamified eye-movement intervention associated with improvements in cognition and reductions in plasma pTau181 and pTau217 in individuals with early-stage MCI.
Research & Knowledge
OptoCeutics
OptoCeutics published research exploring a new light-based technology designed for age-related cognitive decline targeting beta-amyloid and neuroinflammation without side effects.
Research & Knowledge
CogniFit